Navigation Links
SUPERaseIn from Ambion

ProductsSUPERaseIn from Ambion
Company Ambion
Item SUPERaseIn
Price $92.00
Description SUPERaseIn RNase Inhibitor (patent pending) is a protein based inhibitor of nonhuman origin that noncovalently binds and inhibits the most common and troublesome RNases including RNase A, B, C, 1 and T1. SUPERaseIn can be used in any application where RNase contamination could be problematic. It is ideal for in vitro transcription and translation, cDNA synthesis, RT-PCR, and preparation of RNase-free antibodies. Because it inhibits a broader range of RNases than traditional RNase inhibitors, SUPERaseIn is the most effective RNase inhibitor available providing a higher level of protection against degradation.

The most widely used RNase inhibitor is placental ribonuclease inhibitor (RIP). SUPERaseIn is distinct from RIP in that it has a more robust interaction with RNases, does not release active RNases in the absence of DTT, and inhibits a broader range of RNases. While placental ribonuclease inhibitors are effective only against RNase A type enzymes, SUPERaseIn also inhibits RNase 1 and T1. SUPERaseIn does not interfere with other enzymes such as RNA polymerases, reverse transcriptase or Taq polymerase. Additionally, SUPERaseIn is active up to 65C and for a pH range of 5.5 to 8.5.

Info AmbionAmbion
2130 Woodward
Austin, TX 78744
USA

Call Ambion to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-512-795-4221
Customer Service: 512-651-0200
Fax Number: 512-651-0201
Web Site: http://www.ambion.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. SUPERaseIn from Ambion
2. Silencer siRNA Starter Kit from Ambion
3. SlideHyb Glass Array Hybridization Buffer #1 from Ambion
4. mirVana™ miRNA Bioarray Essentials Kit from Ambion
5. SlideHyb Glass Array Hybridization Buffer #1 from Ambion
6. siPORT NeoFX Transfection Agent 1 ml from Ambion
7. siPORT NeoFX Transfection Agent from Ambion
8. DNase I (RNase-free) (2 U/l) from Ambion
9. TURBO DNase (2 U/l) from Ambion
10. Guanylyltransferase (5 U/l) from Ambion
11. 96 well Magnetic-Ring Stand 1 each from Ambion
(Date:2/24/2017)... Feb. 24, 2017  EyeLock LLC, a leader of iris-based ... iris biometric solution on the latest Qualcomm® Snapdragon™ ... Mobile World Congress 2017 (February 27 – ... Hall 3, Stand 3E10. The ... security platform—a combination of hardware, software and ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... ... is proud to announce it has become the premiere team-building cooking event company in San ... world, such as Illumina, HP and Qualcomm, and is ranked #1 in its category on ... to its new team building format, a way for teams to not only interact with ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
(Date:3/22/2017)...  Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... address significant unmet medical needs in rare diseases, ... ended December 31, 2016. "2016 ... we broadened our pipeline and pursued our vision ... with an initial focus on endocrinology," said ...
Breaking Biology Technology: